Cartalax 20mg

Researchers who want to buy Cartalax for research need compound identity, RUO labeling, COA data, purity evidence, and lot-level documentation. Cartalax is listed in PubChem as alanyl-glutamyl-aspartic acid, also known as Ala-Glu-Asp, with the sequence AED and a molecular weight of 333.29 g/mol [1] . Published literature provides scientific context, while batch-specific records support evaluation of the supplied laboratory material.

• Cartalax is a short peptide listed as Ala-Glu-Asp, or AED, in PubChem, where it is also associated with the synonym Cartalax [1].
• In peptide bioregulator literature, Khavinson, Linkova, and coauthors have discussed short peptides in relation to gene expression and model-specific cellular pathways [6] [7].
• Cartalax-related literature examines cartilage, connective tissue, extracellular matrix, chondrocyte, collagen, and mesenchymal stem cell culture models. Those findings apply to the experimental systems studied, not automatically to a catalog product [2] [3] .
• HPLC can support chromatographic peptide purity review, while LC-MS and mass spectrometry can support peptide identity review when method details and batch documentation are available [11] [12].
• Cartalax is supplied for laboratory research by qualified teams, not for consumer, wellness, clinical, or veterinary use.

Fast Answer: What Should Researchers Check Before They Buy Cartalax for Research?

To buy Cartalax for research, evaluate RUO labeling, batch-specific COA documentation, peptide identity, purity testing, and lot traceability before any supplier decision. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Cartalax review should stay focused on research documentation, analytical verification, and published literature boundaries.

What Documentation Should Come First for Cartalax Research?

The first layer is compound identity. Cartalax should align with the AED peptide identity shown in authoritative chemical records, including the Ala-Glu-Asp sequence, molecular formula C12H19N3O8, and molecular weight 333.29 g/mol [1].

The next layer is batch documentation. A research buyer should review the certificate of analysis, test date, purity method, identity method, lot number, and product label together rather than treating any single document as complete evidence.

RUO Labeling Before Research Procurement

RUO labeling should appear before any commercial review. A Cartalax research material listing should make clear that the compound is intended for research purposes and sold for laboratory research use.

Consumer claims and promises about product performance do not replace analytical documentation for the material under evaluation.

What Is Cartalax in Peptide Bioregulator Research?

Cartalax is a short synthetic peptide associated with the sequence Ala-Glu-Asp, often abbreviated AED [1]. In peptide bioregulator literature, short peptides have been studied as signal molecules in model systems, including publications that discuss DNA-peptide interactions, gene expression, and cellular regulatory context [6] [7].

Cartalax is discussed here as a laboratory research peptide requiring documentation review, not a clinical-use material, wellness product, or consumer compound.

Cartalax Peptide Identity and Tripeptide Classification

Cartalax is a synthetic tripeptide because it contains three amino acid residues: alanine, glutamic acid, and aspartic acid [1]. PubChem lists the IUPAC condensed form as H-Ala-Glu-Asp-OH and the sequence as AED [1].

A mismatch between compound name, sequence, formula, or lot details should be resolved before a research procurement decision.

How Does the AED Sequence Connect to Short Peptides?

AED belongs to the short peptide category because it contains only three residues. Khavinson, Linkova, and coauthors have published model-based work proposing that some short peptides can interact with DNA sequence motifs, including a report that modeled AED binding to an ACCT DNA sequence [6].

That literature is mechanistic and model-specific. It informs the research context but does not establish effects of a supplier’s product.

Glutamic Acid and Aspartic Acid in Sequence Documentation

The sequence Ala-Glu-Asp contains glutamic acid and aspartic acid as its second and third residues [1]. Those residues are part of the compound identity, so they belong in sequence verification and supplier documentation.

For technical procurement teams, the key point is consistency. The label, COA, and analytical documentation should point to the same peptide identity rather than using vague naming alone.

Published Literature on Cartalax Bioregulator Research

Published literature around Cartalax overlaps with broader peptide bioregulator research, short peptides, cellular aging models, and chondrogenic differentiation models [2] [4] [7]. Much of this literature comes from a concentrated research network, so source quality and independent corroboration are important.

Khavinson and Linkova Context for Peptide Bioregulators

Khavinson, Linkova, and coauthors have published several papers and reviews on short peptides, peptide bioregulation, and gene expression models [6] [7]. Their systematic review describes peptides as molecules studied across several biological systems and discusses gene expression regulation as a central theme [7].

What Can Literature Show About Cellular Aging Models?

One PubMed-indexed study examined Ala-Glu-Asp and other short peptides in mesenchymal stem cell aging cultures and reported changes in genes including IGF1, FOXO1, TERT, TNKS2, and NF-κB in model-specific conditions [4]. Another in vitro paper reported marker changes in fibroblast aging models, including MMP-9, Ki-67, CD98hc, and caspase-dependent apoptosis markers [5].

Those findings are research observations under the reported conditions, not established effects of a catalog product.

Where Does In Vitro Research Fit Into Cartalax Literature Review?

In vitro research is useful because it allows researchers to examine cell behavior, gene expression, protein synthesis, and pathway markers under controlled model conditions. A 2023 PubMed-indexed paper examined AED peptide and a cartilage polypeptide complex in mesenchymal stem cell chondrogenic differentiation models during replicative aging [3].

The important limitation is that in vitro findings are not product-use guidance. They describe model conditions, not buyer outcomes.

Cartilage and Connective Tissue Research Applications

Cartilage and connective tissue research can provide context for Cartalax because AED appears in studies that discuss chondrogenic differentiation, extracellular matrix markers, and cartilage-related protein synthesis [2] [3]. The research application is the study model, not a product promise.

How Do Cartilage Cells Fit Into In Vitro Models?

Cartilage cells, chondrocyte biology, and chondrogenic differentiation models help researchers study extracellular matrix formation and cartilage-specific markers. The 2023 Cartalax-related paper examined SOX9, aggrecan, type II collagen, and COMP in mesenchymal stem cell culture conditions [3].

These markers are variables measured in the cited experiments, not verified outcomes of a supplier’s product.

Extracellular Matrix, Collagen, and Chondrocyte Context

Cartilage extracellular matrix is commonly described as a network rich in type II collagen, proteoglycans, hyaluronan, and related structural components [8] [10]. Chondrocyte behavior is shaped by cell-matrix interactions, mechanical cues, and signaling pathways within that matrix environment [8] [9].

This helps explain why literature around Cartalax peptide bioregulator research often sits near extracellular matrix, collagen, and chondrocyte terminology. It does not justify unsupported claims for a product listing.

Cellular Pathways and Gene Expression Context

Cartalax research is often described through cellular pathways and gene expression. Published short-peptide literature has examined DNA-peptide interaction models, gene expression markers, and cellular signaling context [6] [7].

Pathway relevance supports interpretation of the literature; it does not establish that a catalog product produces a biological outcome.

Gene Expression Signals Examined in Research

A mesenchymal stem cell aging culture paper examined IGF1, FOXO1, TERT, TNKS2, and NF-κB expression in relation to short peptides including AED [4].

A separate chondrogenic differentiation paper examined SOX9, aggrecan, type II collagen, and COMP in model conditions [3].

Cellular Pathways Related to Cartilage Research

Cartilage pathway discussion can include extracellular matrix signaling, chondrogenic differentiation markers, collagen context, aggrecan context, and chondrocyte-related signaling. Reviews of cartilage extracellular matrix describe integrin-mediated cell-matrix interactions and pathways involved in chondrogenesis [8].

For Cartalax research, those pathways provide a map for interpreting literature. They are not claims about a Pure Lab Peptides product.

Why Is Pathway Context Not a Product Claim?

A pathway is a research framework. It helps researchers organize questions about cell signaling, gene expression, protein synthesis, and model-specific changes.

Cartilage Regeneration Research

Cartilage regeneration research examines biological processes in defined tissue and cell models. Findings in these models do not establish effects or suitability of a Cartalax catalog product.

What Does Regeneration Mean in Biological Research?

In biological research, regeneration refers to a study area involving tissue models, cell differentiation, extracellular matrix formation, and related biological processes. In cartilage-focused literature, researchers may examine markers such as aggrecan, collagen, COMP, and SOX9 when studying chondrogenic differentiation [2] [3].

Literature Boundaries for Research Findings

Several distinctions matter when interpreting the evidence:

• Published literature does not equal product-use guidance.
• Preclinical or in vitro findings should not be converted into human claims.
• A purity percentage does not prove complete compound identity.
• A COA should be batch-specific whenever it is used for procurement review.
• Pathway relevance does not equal a product claim.

Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.

What Should Researchers Know About Evidence Interpretation?

Evidence interpretation starts with source type. A PubChem record supports identity data, a cell culture paper supports model-specific findings, a review summarizes a field, and analytical-method literature supports testing interpretation [1] [7] [11] [12].

This evidence ladder is a practical way to avoid overstatement. Each source type answers a different question.

Study Model Differences Across Tissue Cultures

Tissue cultures differ by cell type, passage state, medium, exposure conditions, marker panel, and analytical endpoint. A mesenchymal stem cell model cannot be treated as the same evidence category as a fibroblast model, even when both involve short peptides [3] [5].

For Cartalax, findings from different cell models need separate interpretation; they cannot be assumed to establish the same effect across systems or preparations.

How Does Source Quality Shape Cartalax Research Review?

A source quality filter should start with peer-reviewed papers, PubMed-indexed abstracts, official databases, and method references. Vendor pages, forum posts, and unsourced summaries should not be used as scientific evidence.

For Cartalax, especially, source quality matters because much of the peptide bioregulator literature comes from a concentrated author network. A careful review should separate primary data, review claims, database identity records, and supplier documentation.

Reproducibility Considerations for Peptide Bioregulator Literature

Reproducibility depends on clear compound identity, defined study conditions, transparent methods, and repeatable analytical endpoints. Analytical validation frameworks also emphasize method characteristics such as specificity, accuracy, precision, range, and robustness for procedure evaluation [14].

For procurement teams, reproducibility begins before the experiment. It starts with making sure the research material and documentation tell the same story.

COA Documentation for Cartalax Peptide Review

A certificate of analysis is a core document for research material review. NIST describes certificates of analysis in reference material contexts as documents that state certified properties for measured materials, which helps explain why COA structure and traceability matter in scientific documentation [16].

For Cartalax peptide review, the COA should be batch-specific when possible. It should not be treated as interchangeable across unrelated lots.

What Should a Certificate of Analysis Identify?

A useful COA should identify the compound name, lot number, test date, testing method, purity result, identity result, and lab source. The COA should be compared against the product label and supplier documentation.

The COA is not the whole quality story. It is one document in a chain that also includes label consistency, analytical methods, storage notes, and lot traceability.

How Does Batch-Specific COA Data Support Procurement Review?

Batch-specific data ties the document to the research material under review. If a COA lacks a lot number or refers to a different batch, it may not support the material being evaluated.

NIST reference material documentation emphasizes traceability and certified property values in measurement contexts [16]. For research peptide procurement, the same general principle applies: documents are most useful when they connect clearly to the specific material.

Purity, Identity, and Analytical Testing Considerations

Purity and identity answer different questions. HPLC can support chromatographic purity review by separating peptide-related species, while mass spectrometry can help confirm whether the observed mass aligns with the expected synthetic peptide identity [11] [12].

A strong documentation package should not rely on a purity number alone. It should pair purity data with identity evidence, method notes, and lot-level consistency.

For a documentation-focused laboratory verification workflow:

1. Verify that the compound name, lot number, and label match across the product page, COA, and supporting documents.
2. Review the batch-specific certificate of analysis.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS, MALDI-TOF-MS, or another suitable analytical method [11].
5. Review chromatogram or mass data when available.
6. Check the COA date and lab source.
7. Record storage and handling documentation in a laboratory record.

How Does HPLC Support Peptide Purity Review?

HPLC is widely used for peptide separation, analysis, and purification, including reversed-phase methods that separate peptides based on chromatographic behavior [12]. In a COA context, HPLC can help show whether a main chromatographic peak dominates under the stated method.

That does not mean HPLC alone proves full identity. Purity review should be paired with identity testing when the research material will be used in sensitive laboratory work.

How Does LC-MS Support Peptide Identity Verification?

Mass spectrometry is well suited for synthetic peptide identity and purity analysis, and LC-MS is commonly used when the peptide sequence is already known and the goal is confirmation [11]. LC-MS can compare observed mass data with the calculated molecular weight expected from the peptide sequence [11] [13].

For Cartalax, the expected molecular weight can be checked against the PubChem identity record for Ala-Glu-Asp [1]. Matching mass evidence strengthens identity review when it is tied to the correct lot.

Mass Spectrometry Details in Cartalax Documentation

Mass spectrometry documentation may include calculated mass, observed mass, ion information, and method notes. LC-MS literature also highlights that synthetic peptides can show structural modifications or impurities related to starting materials, manufacturing, or storage conditions [13].

For technical procurement, the best practice is to read mass data with the COA, label, and HPLC result together. No single field should be isolated from the documentation package.

Peptide Vial Labeling and Lot Traceability

Peptide vial labeling should support clarity, not marketing. The label should identify the compound, lot, catalog specification, and research-use-only status.

If a product listing includes 20mg, treat that amount as a catalog specification that should match the label and documentation.

What Labeling Details Should Research Buyers Compare?

Research buyers should compare compound name, sequence, lot number, catalog specification, storage notes, and RUO language. The goal is consistency across documents.

A mismatch does not always prove a material is unsuitable, but it does create a documentation question. That question should be resolved before procurement approval.

Lot Numbers and Documentation Continuity

Lot numbers connect product pages, COAs, labels, and internal research records. Without lot traceability, it becomes harder to interpret experimental variability or reproduce research conditions.

ISO/IEC 17025 describes competence and valid results for testing and calibration laboratories, which is relevant when procurement teams evaluate external laboratory documentation [15]. Lab identity and method clarity matter because a COA is only as useful as the documentation behind it.

Storage, Handling, and Freeze-Drying Documentation

Freeze-drying, also called lyophilization, is a common stability approach for biological and peptide-related materials, but solid-state materials can still undergo chemical change during storage [17] [18]. That is why documentation matters beyond the day of receipt.

Storage Notes for Laboratory Research Use

A laboratory storage record can include received condition, label statement, storage condition, receipt date, and internal chain-of-custody notes.

This is especially relevant for research peptides because environmental exposure can affect material integrity. Published stability literature shows that solid-state peptide and protein materials can still undergo degradation pathways during storage [17].

What Do Freeze-Drying Details Add to Product Documentation?

Freeze-drying details can help a lab understand the physical form of the research material. Lyophilized solids are often used to support stability, but analytical characterization remains important because dried materials can still change under storage stress [17] [18].

Laboratory Handling Documentation

Useful laboratory handling records include product receipt date, label review, lot match, COA review, storage condition, and internal custodian.

What Supplier Documentation Should Researchers Review Before They Buy Cartalax for Research?

Before researchers buy Cartalax for research, supplier documentation should be reviewed as a package. The package should include RUO labeling, batch-specific COA, analytical testing details, lot traceability, storage documentation, and a clear product-page description.

Verifiable documentation is essential to evaluating a Cartalax research material; broad quality claims do not replace it.

How Do Research Buyers Compare Supplier Documentation?

Research buyers can compare supplier documentation with a simple checklist:

• Verify that Cartalax is labeled for laboratory research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by an identified analytical method.
• Check that the lot number on the COA matches product documentation.
• Compare compound name, molecular weight, and sequence across documentation [1].
• Distinguish published study findings from evidence about the supplied lot.
• Document storage and handling conditions in a laboratory record.

Peptide Catalog Consistency in Procurement Review

For Cartalax, compare the name with the AED and Ala-Glu-Asp identity record [1] . Confirm that the listing, label, and COA refer to the same compound and lot.

What Comes Next Before Ordering Cartalax for Research?

Before ordering Cartalax for research, a technical buyer should review the product page, COA, lot information, identity data, purity method, labeling, and storage documentation. The final question is not whether the page makes strong claims; it is whether the documentation is strong enough for research procurement review.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

What Should the Final Procurement Checklist Confirm?

The final procurement checklist should confirm RUO labeling, compound identity, batch-specific COA, analytical method visibility, and lot traceability. These records do not establish suitability for consumer or clinical use.

For research teams comparing peptide suppliers, prioritize COA availability, transparent labeling, and lot-level documentation. Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

The safest final standard is documentation first. Explore Pure Lab Peptides for RUO peptide compounds with research-focused product information and available documentation.

FAQs

What is Cartalax peptide in research literature?

Cartalax peptide is described in research documentation as Ala-Glu-Asp, a short tripeptide also abbreviated as AED [1] . Researchers can compare the name, sequence, and molecular weight across supplier records to assess identity consistency before procurement.

What should researchers know about Cartalax and cartilage tissue models?

Cartalax and cartilage tissue models should be interpreted as research context only. Published literature has examined AED-related peptide work in chondrogenic differentiation and extracellular matrix marker studies [3]. These models may include cartilage-related markers, but the findings should remain separate from product claims and should be reviewed alongside COA data and batch-specific documentation.

How is cellular senescence discussed in Cartalax research?

Cellular senescence is discussed as a model-specific research topic, not as a product outcome. Cartalax-related literature has examined aging in vitro, gene expression in human mesenchymal research models, and marker panels linked to cellular differentiation [4]. These findings should be read as experimental observations within defined laboratory conditions.

What role do fibroblast models play in Cartalax literature review?

Fibroblast models can help researchers understand how short peptides have been examined in cell-culture systems. Literature on fibroblast functions during their aging has reported marker changes involving cell proliferation, programmed cell death, and caspase 3 in controlled research settings [5]. That context supports literature review, not product positioning or consumer-facing interpretation.

Why should researchers review batch-specific documentation for Cartalax?

Researchers should review batch-specific documentation for Cartalax because it connects the product label, COA, lot traceability, and analytical testing record. A useful documentation package should support compound characterization through matching identity fields, visible purity data, and clear supplier documentation. HPLC and LC-MS may help support purity and identity review when included in the documentation package [11].

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Vladimir Khatskelevich Khavinson

Author profile: RUDN Journal of Medicine Profile

Vladimir Khatskelevich Khavinson authored and coauthored peer-reviewed work on short peptides, gene expression, and peptide bioregulation. His publications examine short-peptide sequences, peptide-DNA interaction models, and gene-expression mechanisms, providing context for interpreting this research literature.

Selected publications:

• Peptide Regulation of Gene Expression: A Systematic Review — Molecules, 2021. DOI: 10.3390/molecules26227053. PMID: [34834147]
• Short Peptides Regulate Gene Expression — Bulletin of Experimental Biology and Medicine, 2016. DOI: 10.1007/s10517-016-3596-7. PMID: [27909961]

Natalia Sergeevna Linkova

Author profile: ORCID

Natalia Sergeevna Linkova’s publications include studies of chondrogenic differentiation, short peptides, and cell models. Her work contributes to the Cartalax-related literature on cartilage, connective tissue, and gene expression under defined experimental conditions.

Selected publications:

• Peptide Regulation of Chondrogenic Stem Cell Differentiation — International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24098415. PMID: [37176122]
• Peptide Regulation of Cell Differentiation — Stem Cell Reviews and Reports, 2020. DOI: 10.1007/s12015-019-09938-8. PMID: [31808038]

REFERENCES

1. National Center for Biotechnology Information. Alanyl-glutamyl-aspartic acid compound record. PubChem. Updated database record.
2. Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Review of peptide regulation in chondrogenic stem cell differentiation models. International Journal of Molecular Sciences. 2023. PMID: 37176122. DOI: 10.3390/ijms24098415.
3. Myakisheva S.N. et al. Study of peptide influence in chondrogenic differentiation models during replicative aging. Advances in Gerontology. 2023. PMID: 37782646.
4. Ashapkin V, et al. Short-peptide modulation of gene expression in mesenchymal stem cell aging cultures. Molecular biology reports. 2020. PMID: 32399807.
5. Lin’kova N.S. et al. Peptide regulation of fibroblast functions during in vitro aging. Bulletin of Experimental Biology and Medicine. 2016. PMID: 27259496. DOI: 10.1007/s10517-016-3370-x.
6. Khavinson V.K., Lin’kova N.S., Tarnovskaya S.I. Short-peptide gene expression and DNA interaction models. Bulletin of Experimental Biology and Medicine. 2016. PMID: 27909961. DOI: 10.1007/s10517-016-3596-7.
7. Khavinson V.K., Popovich I.G., Linkova N.S., Mironova E.S., Ilina A.R. Systematic review of peptide regulation of gene expression. Molecules. 2021. PMID: 34834147. PMCID: PMC8619776. DOI: 10.3390/molecules26227053.
8. Wu Y. et al. Cartilage extracellular matrix and chondrocyte interaction review. BioMed Research International. 2014. PMCID: PMC4052144.
9. Han L., Grodzinsky A.J., Ortiz C. Nanomechanics of cartilage extracellular matrix. Annual Review of Materials Research. 2011. PMID: 22792042. PMCID: PMC3392687. DOI: 10.1146/annurev-matsci-062910-100431.
10. NCBI Bookshelf. Aggrecan and hyaluronan in cartilage extracellular matrix. Electromechanobiology of Cartilage and Osteoarthritis. 2023.
11. Prabhala B.K., Mirza O., Højrup P., Hansen P.R. Synthetic peptide characterization by mass spectrometry. Methods in Molecular Biology. 2015. PMID: 26424265. DOI: 10.1007/978-1-4939-2999-3_9.
12. Mant C.T., Chen Y., Yan Z., Popa T.V. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007. PMCID: PMC7119934. DOI: 10.1007/978-1-59745-430-8_1.
13. Lian Z., Wang N., Tian Y., Huang L. LC-MS characterization review for synthetic peptides. Journal of the American Society for Mass Spectrometry. 2021. PMID: 34110145. DOI: 10.1021/jasms.0c00479.
14. U.S. Food and Drug Administration. Q2(R2) validation of analytical procedures. FDA Guidance Document. 2024.
15. International Organization for Standardization. ISO/IEC 17025 testing and calibration laboratories overview. ISO. Accessed 2026.
16. National Institute of Standards and Technology. Reference materials and certificate documentation overview. NIST. Accessed 2026.
17. Lai M.C., Topp E.M. Solid-state chemical stability of proteins and peptides. Journal of Pharmaceutical Sciences. 1999. PMID: 10229638. DOI: 10.1021/js980374e.
18. Moorthy B.S., Schultz S.G., Kim S.G., Topp E.M. Characterizing protein structure, dynamics, and conformation in lyophilized solids. Methods in Molecular Biology. 2015. PMID: 26446463. PMCID: PMC4671836.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.